We are reporting on a nosocomial outbreak of 213 cases of vancomycin-resistant enterococcus infection involving 2,812 enterococcal isolates from patients over a period of 36 months. In 1990, the Enterococcus faecium vancomycin susceptibility rate was found to be 85.7% (36 of 42 cases), and an incidence of 10.9%o (42 of 383) was noted. The 1991 data showed E.faecium with a vancomycin susceptibility rate of 61.8% (110 of 178) and an incidence of 26.0%,o (178 of 684). Subsequently, in 1992, the incidence ofE.faecium increased to 34.0%yV (599 of 1,745), with a decreased vancomycin susceptibility rate of 25.8% (155 of 599). The E. faecalis vancomycin susceptibility rate remained near 97% (1,768 of 1,823) over the 36-month period. Of 115 vancomycin-resistant enterococcus (VRE) clinical isolates identified by the MicroScan MIC Combo-6 panels (Baxter Healthcare, Sacramento, Calif.), the agar dilution method indicated the resistance rate to be 92.3% (106 of 115) (high level), 3.5% (4 of 115) midlevel, and 3.5% (4 of 115) (low level). Genotypic characterization of 32 different VRE isolates by field-inversion gel electrophoresis demonstrated 19 dissimilar restriction endonuclease patterns, with 9 patterns associated with VRE quinolone resistance. Statistical analysis of case-control data for 32 patients with VRE infections indicated a positive association with intrabdominal surgical procedures (odds ratio, 24.12), multidrug therapy (odds ratio, 37.80), preexposure to vancomycin (odds ratio, 20.21), and death (odds ratio, 17.50).
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Enterococcus species have been recognized as human pathogens since their discovery at the turn of the century and have been commonly characterized as multiple-drugresistant gram-positive cocci (5, 16, 18) . It has been shown that the inappropriate use of antibiotics can potentially lead to the emergence of resistant strains of bacteria (3, 11, 26, 33, 34) . However, the role of enterococci as a virulent group of organisms in mixed infection is still difficult to establish by conventional epidemiology techniques (4) . Advances in molecular probe technology potentiate their use as powerful tools for solving complex problems in epidemiology (6, 15, 24) . One basic problem is that enterococci are frequently isolated as part of the normal human flora and from the surrounding environment (5) . Prior to 1986, vancomycinresistant enterococci (VRE) were considered a clinical rarity. Since 1988, reports of VRE have been limited to a small number of outbreaks (12, 29) . However, within the last 6 years, enterococci have emerged as the second most common cause of nosocomial infections (16, 18 Bacteriologic methods. Catalase-negative, esculin-positive, pyrrolidonyl naphthylamide-positive, gram-positive cocci in short chains were recovered from a variety of clinical sources. The methods of isolation and vancomycin (30 ,g/ml) disk diffusion were performed according to previously described procedures (5, 22) .
The gram-positive MIC Combo-6 panels (Baxter Healthcare, Sacramento, Calif.) were prepared according to the manufacturer's directions. The panels were inoculated by using the MicroScan Prompt system (8, 9) . The panels were incubated for 16 to Restriction endonuclease analysis (REA). For chromosomal DNA, a 10-ml sample of log-phase bacterial cells was centrifuged and washed in 10 ml of TE (Tris-EDTA) buffer. The cells were resuspended in 2 ml of EC buffer (6 mM Tris hydrochloride [pH 7.6], 1 mM NaCl, 100 mM disodium EDTA [pH 7.5], 0.5% Brij, 0.2% sodium deoxycholate, 0.5% sodium lauroylsarcosine) (Sigma Chemical Co., St. Louis, Mo.) of which 1 ml was mixed with 1 ml of 1% InCert Agarose (FMC, Rockland, Maine) prepared in EC buffer. To this suspension, 100 ,ul of lysozyme (Sigma) was added, and 100 ,ul of this mixture was cast into a mold (Pharmacia LKB Biotechnology, Inc., Piscataway, N.J.). The inserts were allowed to solidify and then were incubated at 35°C in 20 ml of EC buffer overnight with gentle shaking. After incubation, the inserts were stored in TE buffer at 55°C overnight. The inserts were stored in TE buffer at 4°C until used. For restriction endonuclease digestion, the inserts were removed from storage, equilibrated in 225 ,ul of sterile water-25 pu1 of React 4 buffer (GIBCO BRL, Gaithersburg, Md.), and incubated overnight at 4°C. Inserts were then supplemented with 30 U of SmaI and incubated at 30°C for 1 h. Following digestion, the inserts were placed in TE buffer for 15 min at 4°C. Before the inserts were loaded into the gel, they were equilibrated in 50% TBE (Tris-Borate-EDTA) buffer for 10 min at 4°C. Thin slices of the inserts were loaded into each of two gels for separating chromosomal DNA by FIGE. Two programs were run to separate DNA fragments with sizes of 48.5 to 485 kb and below 48.5 kb (28) .
RESULTS
In 1991, an investigation of the vancomycin susceptibility of enterococcal isolates had shown an overall increase in the incidence of enterococci (Fig. 1 isolates from blood in 1992. The distribution of other sources for enterococcal isolates in the case-control study is described in Table 2 .
Of the study group, 34% (11 of 32 patients) had abdominal surgery, and 25% (8 of 32) had lower gastrointestinal endoscopy, whereas only 6% of the control group (2 of 35) had abdominal surgery. The calculated odds ratio of 24.12 indicates a positive association between intrabdominal surgeries and acquiring a VRE infection (Table 2) .
Data for patients from whom VRE had been isolated in several services were investigated, and we found no association between the service and VRE infection on the basis of the odds ratio (1.02). The average length of stay for the study group was 52.9 days compared with 28.6 days for the control group. The time between the date of admission and isolation of the VRE was 25 nosocomial infections (1, 3, 14, 17, 18) . Within the genus, E. faecalis, followed by E. faecium and E. durans, is responsible for most human disease (5). HL-aminoglycoside-resistant E. faecalis has been recognized in the United States for nearly a decade (14) . More recently, several intrahospital 
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nosocomial outbreaks have been attributed to HL-aminoglycoside-resistant E. faecalis and ampicillin-resistant E. faecium (1, 19, 33, 34) . Conventional epidemiological techniques are dependent on the presence of phenotypic bacterial properties and lack the ability to detect genotypic changes due to plasmids or transposons (15, 25) . The disadvantage of using plasmid content as an epidemiological marker is the inherent problem in the loss, acquisition, or transfer of plasmids (3, 34) . In this study, our approach was to characterize the chromosomal DNA of the bacterium by REA (4, 15) .
Recent studies have clearly documented that antibioticresistant strains of enterococci can be spread exogenously (patient to patient) in the hospital (1, 19, 29, 33) . In this study, the REA patterns generated by FIGE demonstrated the capability, with this technique, of distinguishing between epidemiologically related isolates of both E. faecium and E. faecalis found in a nosocomial hospital outbreak.
The interesting features of this study are the dissimilarity of the genotypes and their widespread distribution in the hospital but with transient clusters of similar genotypes. There is the possibility that two or more nosocomial outbreaks had occurred on the basis of the dissimilarity in the four REA patterns for E. faecalis, with no strain predominating, and the 15 different patterns for E. faecium, with two predominant strains. In addition, there is the possibility that the two E. faecium strains (with an Ic and a Bb pattern) were superinfections and may have served as a focus for the exogenous transfer of VRE. The E. faecium isolates with a strain Bb pattern were vancomycin-resistant quinolone-susceptible strains, and E. faecium isolates with an Ic pattern were quinolone-resistant VRE strains. These isolates should be further evaluated for plasmids associated with quinolone resistance and experimental triple combination synergism (6, 21) .
The statistical analysis of VRE case-control data using odds ratio analysis as an index of chance occurrence for risk factors indicates a positive association with preexposure to vancomycin (20.21) , multi-antibiotic therapy (37.8), invasive procedures (i.e., sigmoidoscopy and colonoscopy) (24.12) , and length of stay, with a mean difference of 24.3 days. All the features found in this study are consistent with previously reported outbreaks of methicillin-resistant Staphylococcus aureus (26) , gentamicin-resistant E. faecalis (14) , and ampicillin-resistant enterococci (1) , which suggest that VRE with HL resistance are an endemic problem.
We found that patients with VRE infections showed no significant differences in terms of age, gender, and hospital distribution compared with patients with vancomycin-susceptible enterococci. In addition, having a human immunodeficiency virus-positive seroconversion in itself was not a risk factor for acquiring an enterococcal infection on the basis of comparison to our control group. More important considerations for VRE risk factors, are the extent of the patient's immunocompromised condition and the patient's immunosuppressive drug regimens (13, 30) .
Urine was the most common source for enterococcal isolates in both the study and control groups. Enterococci have been implicated in over 15% of all nosocomial urinary tract infections (16) . However, we found vancomycin-resistant E. faecium in various other sources, which included blood, wound, and sputum in which it was most often associated with infection. The most serious infections in our study group involved patients who had abdominal surgery (11 of 32) The sensitivity of automated microbiology systems to detect HL vancomycin and aminoglycoside resistance has been described as inadequate for routine use of the systems (7, 27, 31) . However, we have found the MicroScan automated microbiology and data management system to be a reliable system for the identification of enterococci and the detection of VRE.
Enterococci can be a normal component in the normal flora of the human gut, but they have the potential to cause serious infections. Patients receiving large enough doses of antibiotics could be predisposed to colonization by enterococci, leaving them at risk for developing an enterococcal infection (30) . Colonization in our study group (10 of 32 patients) versus the control group (19 of-35) was calculated to an odds ratio of 2.61. Within this group of patients with colonized enterococci, those receiving recent vancomycin therapy before or at the time of colonization were placed at a higher risk for developing a serious VRE infection. This finding appears to be consistent with other data from our study showing that multi-antibiotic therapy (odds ratio, 37.8) increases the risk of VRE infection. Thus, it appears that the widespread use of glycopeptides needs to be reevaluated in an effort to reduce the risk of VRE infections (10, 20) . Prescribers should be encouraged to seek consultation with an infectious disease specialist and microbiologist when considering a glycopeptide in the treatment of Clostridium difficile-associated diarrheal disease, methicillin-resistant S. aureus infections, and uncomplicated urinary tract infections.
